Arrowhead Pharmaceuticals Inc. (ARWR)

21.97
0.18 0.83
NASDAQ : Health Technology
Prev Close 21.79
Open 21.47
Day Low/High 20.42 / 22.08
52 Wk Low/High 9.56 / 22.74
Volume 21.00M
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.02B
EPS -0.70
P/E Ratio 305.00
Div & Yield N.A. (N.A)
First Week of ARWR June 2018 Options Trading

First Week of ARWR June 2018 Options Trading

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 196 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At 29th Annual Piper Jaffray Healthcare Conference

Arrowhead To Present At 29th Annual Piper Jaffray Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: 29th Annual Piper Jaffray Healthcare Conference - New York, November 28-29,...

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 17, 2017, eight new employees were awarded "inducement" grants of options under...

Arrowhead Presents Promising Preclinical Data On Development Of ARO-AAT For Treatment Of Alpha-1 Liver Disease At Liver Meeting® 2017

Arrowhead Presents Promising Preclinical Data On Development Of ARO-AAT For Treatment Of Alpha-1 Liver Disease At Liver Meeting® 2017

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented data from studies demonstrating promising preclinical safety and efficacy of ARO-AAT, a second-generation investigational medicine for the treatment of alpha-1...

Arrowhead Pharmaceuticals To Present Preclinical Data On ARO-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals To Present Preclinical Data On ARO-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's...

Arrowhead To Present At Chardan Gene Therapy Conference

Arrowhead To Present At Chardan Gene Therapy Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Chardan Gene Therapy Conference - New York, October 10, 2017 October...

Arrowhead Data Reveal Important Considerations For Future Hepatitis B Treatment

Arrowhead Data Reveal Important Considerations For Future Hepatitis B Treatment

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic hepatitis B virus (HBV) infection, in a Phase 2 clinical study in...

Arrowhead Hosts Investor & Analyst R&D Day To Introduce TRiM™ Platform And Lead RNAi-based Drug Candidates

Arrowhead Hosts Investor & Analyst R&D Day To Introduce TRiM™ Platform And Lead RNAi-based Drug Candidates

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), is hosting an investor & analyst R&D day in New York today to introduce its proprietary Targeted RNAi Molecule (TRiM TM) platform and review its pipeline of RNAi...

Arrowhead To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Arrowhead To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming event: 2017 Cantor Fitzgerald Global Healthcare Conference - New York, September...

Arrowhead Pharmaceuticals To Host R&D Day On RNAi-Based Therapies

Arrowhead Pharmaceuticals To Host R&D Day On RNAi-Based Therapies

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development Day to discuss its pipeline of RNAi-based therapies on September 14 in New York City.

Arrowhead Reports Fiscal 2017 Third Quarter Results

Arrowhead Reports Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Thursday, August 3, 2017, at 4:30 p.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 5, 2017, eleven new employees were awarded "inducement" grants of options under Rule...

Arrowhead Pharmaceuticals Stock Sees Short Interest Fall 12.3%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,594,692 share decrease in total short interest for Arrowhead Pharmaceuticals Inc , to 11,413,501, a decrease of 12.26% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Arrowhead Reports Fiscal 2017 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, May 3, 2017, at 4:30 p.

Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented clinical data from a Phase 1a/1b study of ARC-AAT, the company's prior generation investigational medicine that was being studied for the treatment of liver disease...

Arrowhead Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, the company's prior generation investigational medicines that were being studied...

Arrowhead Pharmaceuticals Announces Presentations At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the...

Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a...

Take a Look at These Stocks Poised to Trade Higher

Take a Look at These Stocks Poised to Trade Higher

These 5 stocks under $10 look poised to potentially trade higher.

These 5 Stocks Under $10 Could Explode Higher

These 5 Stocks Under $10 Could Explode Higher

Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.

Arrowhead Reports Fiscal 2017 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended December 31, 2016.

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Monday, February 6, 2017, at 4:30 p.

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm, Robbins Arroyo LLP, announces that a class action complaint was filed against Arrowhead Pharmaceuticals, Inc.

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

Here are some names that have caught our eye.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc.

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded to the announcement by Silence Therapeutics plc that it acquired, in the open-market, an equity stake of 6,000,359 Arrowhead shares, representing 8.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

TheStreet Quant Rating: D (Sell)